Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Biospace

Published November 16, 2026 · Updated November 17, 2026

BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio

Read the full story at Biospace

Psychedelics · Serious adverse events mar robust efficacy data for Helus' psychedelic in major depression. November 16, 2026. ·. 3 min read. ·.

Surfaced by this Google Alert

  • Psychedelics